Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation.

Abstract

We read with great interest the meta‐analysis by Grigg et al,1 which evaluated the role of the mechanistic target of rapamycin (mTOR) inhibitors (sirolimus or everolimus) in patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT). The authors found that mTOR‐inhibitor based immunosuppression was associated with prolonged recurrence‐free and overall survival. Although these findings could motivate the reader to systematically prescribe mTOR inhibitors in patients with HCC, there are some important considerations to be taken into account first.